INF904 Phase 2a data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by the end of September to early November 2025Phase 1/2 data announced by Staidson BioPharmaceuti ...

Consumer Reports and Unleaded Kids evaluated baby food brands for compliance with California’s AB899 requiring heavy metal ...

Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in ...

Conference call to provide business updates today, August 6 at 1:30 p.m. PT / 4:30 p.m. ET FOSTER CITY, Calif., August 06, ...

Ultragenyx Pharmaceutical RARE reported second-quarter 2025 loss of $1.17 per share, narrower than the Zacks Consensus ...

Bayer AG (BAYRY) reported second-quarter 2025 core earnings of 35 cents per American Depositary Receipt (ADR), which ...

Q2 2025 Earnings Call Transcript August 5, 2025 Harmony Biosciences Holdings, Inc. misses on earnings expectations. Reported ...

Global breast imaging market projected to reach $8.69 billion by 2030, with IzoView addressing key clinical and commercial trends driving demand ...

Leqvio can now be used alone, without addition of statin therapy, as adjunct to diet and exercise for LDL-C reduction in patients with hypercholesterolemia (high ...

Detailed price information for Ionis Pharmaceuticals (IONS-Q) from The Globe and Mail including charting and trades.

Which One is Right for You?Botulinum toxin injections are among the most popular non-surgical cosmetic treatments available today, offering effective solutions for reducing wrinkles and fine lines.

Numerous recalls have been initiated in 2025 due to the potential for damaged products, foodborne illness, contamination and ...